Related references
Note: Only part of the references are listed.The mTOR signaling pathway as a treatment target for intracranial neoplasms
Doreen Pachow et al.
NEURO-ONCOLOGY (2015)
Association of miR-193b Down-regulation and miR-196a up-Regulation with Clinicopathological Features and Prognosis in Gastric Cancer
Yong-Ping Mu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor- κB1/MMP9 signaling pathway
Tian-Quan Yang et al.
CANCER SCIENCE (2014)
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma
Joseph Thaddeus Beck et al.
CANCER TREATMENT REVIEWS (2014)
Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma
Carlos Rodrigo Gil del Alcazar et al.
CLINICAL CANCER RESEARCH (2014)
Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR
Song Lin et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2014)
A neurocentric perspective on glioma invasion
Vishnu Anand Cuddapah et al.
NATURE REVIEWS NEUROSCIENCE (2014)
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells
Jenna Kahn et al.
NEURO-ONCOLOGY (2014)
miR-18a Inhibits CDC42 and Plays a Tumour Suppressor Role in Colorectal Cancer Cells
Karen J. Humphreys et al.
PLOS ONE (2014)
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma
Emanuela Minna et al.
ONCOTARGET (2014)
The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
Beatrice Gini et al.
CLINICAL CANCER RESEARCH (2013)
MicroRNA-199a-3p is downregulated in gastric carcinomas and modulates cell proliferation
W. Peng et al.
GENETICS AND MOLECULAR RESEARCH (2013)
MicroRNA-199a-3p Regulates Endometrial Cancer Cell Proliferation by Targeting Mammalian Target of Rapamycin (mTOR)
Dong Wu et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2013)
Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics
Naif AlQurashi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Protective Effects of the mTOR Inhibitor Everolimus on Cytoskeletal Injury in Human Podocytes Are Mediated by RhoA Signaling
Stefanie Jeruschke et al.
PLOS ONE (2013)
Molecular Mechanisms of Regulation and Action of microRNA-199a in Testicular Germ Cell Tumor and Glioblastomas
Shen Gu et al.
PLOS ONE (2013)
MicroRNAs involved in chemo- and radioresistance of high-grade gliomas
Andrej Besse et al.
TUMOR BIOLOGY (2013)
The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
Brian M. Slomovitz et al.
CLINICAL CANCER RESEARCH (2012)
Role of mTOR Signaling in Tumor Cell Motility, Invasion and Metastasis
Shile Huang et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2012)
MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma
YuXiang Fang et al.
HEPATOLOGY (2012)
A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration
Raymond Ng et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells
Francesca Fornari et al.
CANCER RESEARCH (2010)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins
Medhi Wangpaichitr et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
MTOR-targeted therapy of cancer with rapamycin derivatives
S Vignot et al.
ANNALS OF ONCOLOGY (2005)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
E Jacinto et al.
NATURE CELL BIOLOGY (2004)
Share Paper
